Montelukast as an Add-on Drug in Induced Azotemia in Humans Following Gastroenteritis
| Author | Farzane Moradi Shamami | en |
| Author | Parsa Yousefichaijan | en |
| Author | Mojtaba Hashemi | en |
| Author | Fatemeh Dorreh | en |
| Author | Ali Arjmand | en |
| Author | Saeed Karimi Matloub | en |
| Author | Masoud Rezagholizamenjany | en |
| Orcid | Parsa Yousefichaijan [0000-0002-6243-431X] | en |
| Orcid | Mojtaba Hashemi [0000-0001-7162-2446] | en |
| Orcid | Fatemeh Dorreh [0000-0003-2568-9169] | en |
| Orcid | Masoud Rezagholizamenjany [0000-0002-5824-2366] | en |
| Issued Date | 2022-05-31 | en |
| Abstract | Background: Gastroenteritis, as a rare and heterogeneous condition, is characterized by patchy or diffuse infiltration of gastrointestinal tissue. Induced azotemia in humans following gastroenteritis has been evaluated in some studies. Objectives: The aim of present study was to evaluate the effect of montelukast on induced azotemia in humans following gastroenteritis. Methods: This study examined children with gastroenteritis with moderate dehydration and more than 3 years of age. The cases had a glomerular filtration rate (GFR) less than 90 and were evaluated in two groups of control (n = 20) and intervention (n = 20). Montelukast (5-mg tablets) was given to patients in the intervention group for 5 days. Normal saline at a rate of 20 cc/kg was given to both groups within 20 minutes until clinical symptoms improved. Finally, the improvement of renal function was evaluated and compared between the 2 groups using SPSS. Results: Out of 40 evaluated patients, the mean age of the control and intervention groups was 5.52 and 5.15 years, respectively. Also, 13 cases (65.0%) in the control group and 9 cases (45.0%) in the control group were males. The mean creatinine (Cr) was significantly reduced after treatment in the intervention group (P = 0.001). Also, the mean GFR after treatment was significantly higher in the intervention group (P = 0.001), and GFR improvement duration was significantly lower in the intervention group (P = 0.002). Conclusions: Montelukast as an add-on drug was effective in reducing the time of GFR enhancement; thus, we can consider it as an add-on drug in azotemia. | en |
| DOI | https://doi.org/10.5812/numonthly-123956 | en |
| URI | https://brieflands.com/journals/num/articles/123956 | en |
| Keyword | Montelukast | en |
| Keyword | Azotemia | en |
| Keyword | Gastroenteritis | en |
| Publisher | Brieflands | en |
| Title | Montelukast as an Add-on Drug in Induced Azotemia in Humans Following Gastroenteritis | en |
| Type | Research Article | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- num-14-2-123956.pdf
- Size:
- 120.07 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF